Can-Fite BioPharma Ltd.

386 articles with Can-Fite BioPharma Ltd.

• Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

  3/16/2023

  Can-Fite BioPharma Ltd. announced today that Dr. Sari Fishman, the Company’s Vice President of Business Development, will participate in the BIO-Europe Spring® partnering conference in Basel, Switzerland from March 20 to 22, 2023.

• Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

  3/13/2023

  Can-Fite BioPharma Ltd. announced today that patients with decompensated cirrhosis, an advanced form of cirrhosis associated with liver failure for which there are no therapeutic options other than liver transplantation, will be treated with Namodenoson at the Soroka Medical Center in Israel under compassionate use.

• Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo

  2/14/2023

  Can-Fite BioPharma Ltd. announced that Purinergic Signalling, a peer-reviewed scientific journal focused on molecules which target adenosine receptors, published an article titled “Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects" authored by Can-Fite’s CEO Dr.

• Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

  1/24/2023

  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its anti-cancer drug Namodenoson significantly inhibits the growth of pancreatic carcinoma as a stand-alone treatment.

• Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow

  1/10/2023

  Can-Fite BioPharma Ltd. announced today it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis.

• Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

  12/28/2022

  Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, provided an update on its clinical program for Namodenoson in the treatment of hepatocellular carcinoma, the most common form of liver cancer.

• Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis

  12/8/2022

  Can-Fite BioPharma Ltd. today announced progress achieved in the development of Piclidenoson for` the treatment of osteoarthritis in dogs by the Company’s veterinary commercialization partner Vetbiolix, which is covering all costs associated with veterinary clinical development.

• Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

  11/25/2022

  Can-Fite BioPharma Ltd. today announced financial results for the quarter ended September 30, 2022.

• Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

  11/2/2022

  Can-Fite BioPharma announced today the Company’s CEO, Dr. Pnina Fishman, will deliver a presentation titled “Piclidenoson for the Treatment of Psoriasis: Clinical Development and Mechanism of Drug Action” at the 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases on November 2, 2022.

• Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®

  10/25/2022

  Can-Fite BioPharma Ltd. announced today that a poster entitled “Complete Response Induced by Namodenoson, an A3 Adenosine Receptor Agonist, in a Patient with Advanced Hepatocellular Carcinoma”

• Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

  10/13/2022

  Can-Fite BioPharma Ltd. announced today the Company’s CEO Dr. Pnina Fishman will present its liver drug candidate, Namodenoson, at the H.C. Wainwright 6th Annual Conference.

• Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

  9/12/2022

  Can-Fite BioPharma Ltd. announced today that Dr. Kim A. Papp, MD, PhD, presented new data from the Company’s recently completed Phase III COMFORT™ study.

• Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update

  8/25/2022

  Can-Fite BioPharma Ltd today announced financial results for the quarter ended June 30, 2022.

• Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

  8/23/2022

  Can-Fite BioPharma Ltd announced today its liver drug candidate Namodenoson has been approved for compassionate use for the treatment of patients with advanced liver cancer in Romania.

• Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress

  8/22/2022

  Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31 st European Academy of Dermatology and Venerology Congress.

• Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

  8/17/2022

  Can-Fite BioPharma Ltd. announced today that hrough a development and commercialization agreement signed with Vetbiolix in June of 2021, Piclidenoson is set to enter a clinical trial for the treatment of osteoarthritis in dogs.

• Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

  7/11/2022

  Further analysis of Phase III COMFORT ™ data show Piclidenoson’s superior safety profile and higher patient compliance compared to Otezla ®.

•  Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis

  6/29/2022

  Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis.

• Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

  6/24/2022

  Can-Fite BioPharma Ltd. today announced its study titled “A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model” was published in the peer-reviewed journal Andrologia.

• Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal

  6/9/2022

  Data suggest Piclidenoson and Namodenoson could potentially be the first A3AR agonists to achieve FDA approval and provide clinicians with new oral and safe drugs in the arsenal for fighting psoriasis, liver cancer, and NASH.